A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov ID: NCT03254927

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03254927. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.

Study identification

NCT ID: NCT03254927
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Celldex Therapeutics; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Advanced Head and Neck Squamous Cell Carcinoma

Interventions

CDX-3379 and cetuximab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 27, 2018 (Actual)
Primary completion: Sep 16, 2020 (Actual)
Completion: Dec 16, 2020 (Actual)
Last update posted: Apr 3, 2023

2018 – 2020

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
The University of Arizona Cancer Center	Tucson	Arizona	85724	—
Yale Cancer Center	New Haven	Connecticut	06511	—
Emory University Winship Cancer Institute	Atlanta	Georgia	30322	—
Rush University Medical center	Chicago	Illinois	60612	—
Washington University School of Medicine	St Louis	Missouri	63110	—
University of Cincinnati	Cincinnati	Ohio	45267	—
University of Pennsylvania Hospital, Abramson Cancer Center	Philadelphia	Pennsylvania	19104	—
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03254927, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 3, 2023 · Synced Nov 15, 2026